Effectiveness of baricitinib and tofacitinib compared with bDMARDs in RA: results from a cohort study using nationwide Swedish register data
Rheumatology (Oxford). 2022. Epub ahead of print doi: 10.1093/rheumatology/keac068
View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.
Rheumatology (Oxford). 2022. Epub ahead of print doi: 10.1093/rheumatology/keac068
Clin Rheumatol. 2022 Jan 1. Epub ahead of print doi: 10.1007/s10067-021-05908-z
ACR Open Rheumatol. 2021. Epub ahead of print. doi: 10.1002/acr2.11380
Rheumatology (Oxford). 2021. Epub ahead of print. doi: 10.1093/rheumatology/keab861
J Crohns Colitis. 2022 Jan 28;16(1):27-38 doi: 10.1093/ecco-jcc/jjab133
The authors highlighted a significantly greater clinical remission rate at Week 52 for vedolizumab SC versus placebo in patients with moderately to severely active CD. This study aimed to report results from VISIBLE 2 which evaluated a new SC vedolizumab formulation as maintenance treatment in adults with moderately to severely active CD.
Ann Rheum Dis. 2021 Apr 27;80(8):1004–13.
Please click the links below to go to the CSF review of each paper
Lancet. 2021;398(10315):1984–96
Rheumatology (Oxford). 2021. Epub ahead of print. doi: 10.1093/rheumatology/keab740.
RMD Open. 2021;7(3):e001838